CVS — CVS Health Corporation
NYSE
Q4 2025 Earnings Call Summary
February 10, 2026
CVS Health Q4 2025 Earnings Call Summary
1. Key Financial Results and Metrics
- Q4 2025 Results:
- Adjusted Operating Income: $2.6 billion
- Adjusted Earnings Per Share (EPS): $1.09
- Revenue: Over $105 billion, an 8% increase year-over-year
- Full Year 2025 Results:
- Adjusted EPS: $6.75, exceeding initial expectations by approximately 15%
- Operating Cash Flow: $10.6 billion
- Total Revenue: Over $400 billion
2. Strategic Updates and Business Highlights
- Aetna Performance:
- Improved adjusted operating income by over $2.6 billion year-over-year.
- Received the inaugural Press Ganey Health Plan of the Year award for quality and innovation.
- Pharmacy Services:
- Significant growth in Caremark and Pharmacy Services, with a focus on managing drug costs and improving client relationships.
- Successful transition to cost-based reimbursement, enhancing transparency in the pharmacy market.
- Health Care Delivery:
- Continued focus on in-home health evaluations through Signify, which serves over 3.5 million consumers annually.
- Expansion of services through partnerships like Oak Street Health.
3. Forward Guidance and Outlook
- 2026 Guidance:
- Revenue expected to exceed $400 billion.
- Adjusted EPS guidance reaffirmed at $7 to $7.20.
- Cash flow from operations expected to be at least $9 billion.
- Medicare Advantage:
- Commitment to return to target margins by 2028, despite challenges posed by the proposed 2027 Medicare Advantage rates.
4. Challenges and Points of Concern
- Medicare Advantage Rates:
- Proposed rates for 2027 are viewed as inadequate, potentially impacting margin recovery efforts.
- Membership Declines:
- Aetna experienced a slight decline in medical members, with a loss of approximately 500,000 year-over-year.
- Health Care Costs:
- Elevated medical cost trends remain a concern across all segments, particularly in Medicare and Medicaid.
- Regulatory Environment:
- Uncertainty surrounding FTC proposals and PBM legislation could impact CVS's ability to negotiate effectively in the supply chain.
5. Notable Q&A Insights
- Medicare Advantage Strategy:
- CVS remains committed to improving Aetna's margins despite the disappointing advanced rate notice for 2027.
- PBM Legislation:
- CVS supports transparency in the supply chain but is cautious about how regulatory changes may affect their negotiation capabilities.
- Membership Dynamics:
- Growth in commercial membership is attributed to better retention and innovative products, while the individual exchange and government segments face challenges.
- Technology Investments:
- CVS is leveraging AI and technology to enhance consumer engagement and streamline operations, with expectations of significant advancements in 2026.
Overall, CVS Health reported a strong financial performance in 2025 but faces challenges in the Medicare Advantage space and ongoing regulatory pressures. The company remains optimistic about its strategic initiatives and outlook for 2026.